Polycystic Kidney Disease Drugs Market - Top Companies and Manufacturers

Companies Dominating the Polycystic Kidney Disease Drugs Landscape

Otsuka Pharmaceutical Co., Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis

Exelixis, Inc.
XORTX Therapeutics, Inc.
AstraZeneca PLC
Manros Therapeutics
Regulus Therapeutics Inc.
Reata Pharmaceuticals, Inc.
Pano Therapeutics, Inc.
Taro Pharmaceutical Industries Ltd.
GlaxoSmithKline plc.

Browse Key Market Insights with Data Illustration:

Polycystic Kidney Disease Drugs Market Size, Growth Forecasts 2037

In the News

XORTX Therapeutics Inc. declared the positive outcomes from XRX-OXY-101 (“PK Clinical Trial”). The outcomes showed an increase in oral bioavailability for two versions compared to a control formulation in advance of ADPKD's late-stage phase 3 registration trial.
Pano Therapeutics, Inc. has acquired the privately-held NovaTarg Therapeutics, Inc. to strengthen Pano Therapeutic Inc’s drug discovery and development capabilities and enhance its portfolio.

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of polycystic kidney disease drugs is evaluated at USD 571.38 million.

The polycystic kidney disease drugs market size was over USD 513.94 million in 2024 and is poised to exceed USD 1.21 billion by 2037, witnessing over 6.8% CAGR during the forecast period i.e., between 2025-2037. The surge in the incidence of autosomal dominant polycystic kidney diseases (ADPKD), and growing initiatives to raise awareness about PKDs will boost the market growth.

North America industry is predicted to dominate majority revenue share by 2037, attributed to rise in per capita income, along with rising awareness of the early diagnosis of chronic kidney diseases as of the advancement in the medical array in the region.

The major players in the market are Otsuka Pharmaceutical Co., Ltd., Exelixis, Inc., XORTX Therapeutics, Inc., AstraZeneca PLC, Manros Therapeutics, Regulus Therapeutics Inc., Reata Pharmaceuticals, Inc., Pano Therapeutics, Inc., Taro Pharmaceutical Industries Ltd., GlaxoSmithKline plc.

Polycystic Kidney Disease Drugs Market - Top Companies and Manufacturers

Companies Dominating the Polycystic Kidney Disease Drugs Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

What is the size of the polycystic kidney disease drugs market?

Why is the polycystic kidney disease drugs sector gaining traction in near future?

Which region accounted for the largest polycystic kidney disease drugs industry share?

Who are the major polycystic kidney disease drugs players?